Head-to-head evidence
GZR18 vs XW003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
GZR18
Developed by Gan & Lee Pharmaceuticals
NCT06737042 · Phase 2 · completed
The study randomized 326 participants and used quadruple masking with placebo and tirzepatide comparator arms; its primary endpoint was the clinical outcome of percentage change in body weight. Because the primary comparison has not yet been reported, it cannot establish whether GZR18 met its efficacy objective.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
XW003
Developed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This randomized, triple-blind, placebo-controlled Phase 3 trial (n=664) in adults with overweight or obesity found that ecnoglutide (XW003) produced significantly greater weight loss than placebo at 40 weeks across all three doses tested, up to 13.2% versus about 0.1% with placebo (p<0.0001 for every dose).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07073417 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR18's landscape · XW003's landscape